Evolutionarily conserved inhibitory uORFs sensitize Hox mRNA translation to start codon selection stringency.
Ivaylo P IvanovJames A SabaChen-Ming FanJi WangAndrew E FirthChune CaoRachel GreenThomas E DeverPublished in: Proceedings of the National Academy of Sciences of the United States of America (2022)
Translation start site selection in eukaryotes is influenced by context nucleotides flanking the AUG codon and by levels of the eukaryotic translation initiation factors eIF1 and eIF5. In a search of mammalian genes, we identified five homeobox ( Hox ) gene paralogs initiated by AUG codons in conserved suboptimal context as well as 13 Hox genes that contain evolutionarily conserved upstream open reading frames (uORFs) that initiate at AUG codons in poor sequence context. An analysis of published cap analysis of gene expression sequencing (CAGE-seq) data and generated CAGE-seq data for messenger RNAs (mRNAs) from mouse somites revealed that the 5' leaders of Hox mRNAs of interest contain conserved uORFs, are generally much shorter than reported, and lack previously proposed internal ribosome entry site elements. We show that the conserved uORFs inhibit Hox reporter expression and that altering the stringency of start codon selection by overexpressing eIF1 or eIF5 modulates the expression of Hox reporters. We also show that modifying ribosome homeostasis by depleting a large ribosomal subunit protein or treating cells with sublethal concentrations of puromycin leads to lower stringency of start codon selection. Thus, altering global translation can confer gene-specific effects through altered start codon selection stringency.
Keyphrases
- genome wide
- transcription factor
- gene expression
- genome wide identification
- single cell
- dna methylation
- poor prognosis
- genome wide analysis
- binding protein
- induced apoptosis
- rna seq
- copy number
- big data
- minimally invasive
- cell death
- systematic review
- cell cycle arrest
- cell proliferation
- oxidative stress
- working memory
- randomized controlled trial
- signaling pathway